Assessing the Feasibility of the Patient-Reported Outcomes Based Model for Community Care of Patients With Axial Spondyloarthritis Via a Type 1 Pilot Hybrid Effectiveness-Implementation Trial Using the RE-AIM Framework

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorSingapore General Hospital

About this trial

The goal of this clinical trial is to facilitate the implementation of PROMs-based care for patients with axial spondyloarthritis.

The main questions it aims to answer are:

* What are the barriers, facilitators and strategies to implement PROMs-based care? * Can the PROMise algorithm successfully review and postpone appointments of eligible patients? * How feasible is PROMs-based care in patients with axial spondyloarthritis?

Researchers will implement PROMs-Based care and see if PROMs-Based care is feasible and understand patient's opinions on PROMs-Based care implemented.

Participants will:

* Be randomized to either receive intervention (PROM-based care) or control (usual care). Randomisation means assigning you to one of two groups by chance, like tossing a coin or rolling dice. * That receive PROMs-based care, will be sent PROMs questionnaires that ask them about their health conditions via SMS at a regular interval of 4 months. * Have their appointments postponed by 4 months, if the PROMise algorithm with specific thresholds (with overview from the rheumatology care team) assess their condition as stable through their blood test results and PROMs questionnaire. * Have a cap of 12 months between physician visits.

Eligibility criteria

Qualifiers

diagnosed with axial spondyloarthritis according to the 2009 ASAS Classification Criteria of AxSpA

has been receiving care in Singapore General Hospital for at least 6 months

aged 21 years and above

Disqualifiers

Bath Ankylosing Spondylitis Disease Activity Index score of >4

Trial design

Treatments tested in this trial

  • PROMise Model of Care

Treatment groups

70 Participants
are divided into 2 treatment groups

Sponsors and collaborators